Back to Search Start Over

Five commercially-available antibodies react differentially with allelic forms of human HLA-DR beta chain.

Authors :
Houtman M
Dzebisashvili A
Dubnovitsky A
Kozhukh G
Rönnblom L
Klareskog L
Malmström V
Padyukov L
Source :
Molecular immunology [Mol Immunol] 2022 Dec; Vol. 152, pp. 106-110. Date of Electronic Publication: 2022 Oct 27.
Publication Year :
2022

Abstract

Allelic variants of HLA-DRB1 have been associated with a variety of autoimmune and infectious diseases. Although the precise molecular mechanisms by which HLA-DRB1 alleles predispose to a particular disease are currently unclear, it has been shown that mRNA expression levels of HLA-DRB1 are dependent on the different alleles. We aimed to measure HLA-DR beta chain levels in peripheral blood mononuclear cells of individuals carrying HLA-DRB1*03:01/*04:01 and HLA-DRB1*03:01/*15:01 alleles by western blotting, using five commercially-available HLA-DRB antibodies. We observed highly heterogeneous binding of the tested antibodies to the different allelic forms of the HLA-DR beta chain. Overall, we show that current immunological research that employs available antibodies to detect HLA-DR beta chains is biased towards detection of specific variants of the protein; this may cause significant discrepancy in quantification of protein expression in a heterogeneous human population.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no conflicts of interest regarding this publication.<br /> (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Details

Language :
English
ISSN :
1872-9142
Volume :
152
Database :
MEDLINE
Journal :
Molecular immunology
Publication Type :
Academic Journal
Accession number :
36327907
Full Text :
https://doi.org/10.1016/j.molimm.2022.10.008